# A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

> **NCT03275740** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 58 (actual)

## Conditions studied

- Healthy
- Primary Immune Thrombocytopenia
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

## Interventions

- **DRUG:** PF-06755347 intravenous healthy participant
- **DRUG:** Placebo intravenous healthy participant
- **DRUG:** PF-06755347 subcutaneous healthy participant
- **DRUG:** Placebo subcutaneous healthy participant
- **DRUG:** PF-06755347 subcutaneous ITP

## Key facts

- **NCT ID:** NCT03275740
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-17
- **Primary completion:** 2023-01-06
- **Final completion:** 2023-01-06
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** The Sponsor has decided to terminate the above referenced clinical study for business reasons. There were no safety concerns that led to this decision and there was no impact to participant safety.
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03275740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03275740, "A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03275740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*